X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (103) 103
index medicus (84) 84
male (74) 74
female (73) 73
oncology (69) 69
aged (67) 67
middle aged (67) 67
adult (55) 55
lung neoplasms - pathology (54) 54
lung neoplasms - drug therapy (52) 52
respiratory system (49) 49
chemotherapy (48) 48
cancer (47) 47
carcinoma, non-small-cell lung - drug therapy (43) 43
aged, 80 and over (38) 38
life sciences (34) 34
lung cancer (34) 34
lung neoplasms - genetics (32) 32
carcinoma, non-small-cell lung - pathology (31) 31
lung neoplasms - mortality (29) 29
prognosis (27) 27
treatment outcome (26) 26
lung cancer, non-small cell (25) 25
antineoplastic combined chemotherapy protocols - therapeutic use (24) 24
neoplasm staging (24) 24
carcinoma, non-small-cell lung - mortality (22) 22
adenocarcinoma (21) 21
survival (21) 21
carcinoma, non-small-cell lung - genetics (20) 20
antineoplastic agents - therapeutic use (19) 19
non-small cell lung cancer (18) 18
prospective studies (18) 18
hematology, oncology and palliative medicine (17) 17
mutation (17) 17
care and treatment (16) 16
gefitinib (16) 16
protein kinase inhibitors - therapeutic use (16) 16
pulmonary/respiratory (16) 16
france (15) 15
disease-free survival (14) 14
[ sdv.can ] life sciences [q-bio]/cancer (13) 13
docetaxel (13) 13
immunohistochemistry (13) 13
lung neoplasms (13) 13
lung neoplasms - therapy (13) 13
survival analysis (13) 13
adenocarcinoma - drug therapy (12) 12
adenocarcinoma - pathology (12) 12
carcinoma (12) 12
cisplatin (12) 12
crizotinib (12) 12
research (12) 12
survival rate (12) 12
patients (11) 11
retrospective studies (11) 11
tumors (11) 11
carcinoma, non-small-cell lung - therapy (10) 10
clinical trials (10) 10
follow-up studies (10) 10
mesh : humans (10) 10
mesh : lung neoplasms (10) 10
quinazolines - therapeutic use (10) 10
risk factors (10) 10
tomography, x-ray computed (10) 10
trial (10) 10
adenocarcinoma - genetics (9) 9
apoptosis (9) 9
kaplan-meier estimate (9) 9
lung neoplasms - diagnosis (9) 9
oncology, experimental (9) 9
open-label (9) 9
receptor, epidermal growth factor - genetics (9) 9
[ sdv.spee ] life sciences [q-bio]/santé publique et épidémiologie (8) 8
abridged index medicus (8) 8
analysis (8) 8
biomarkers, tumor - genetics (8) 8
carboplatin (8) 8
cell lung-cancer (8) 8
cisplatin - administration & dosage (8) 8
egfr (8) 8
egfr mutations (8) 8
gene (8) 8
lung neoplasms - metabolism (8) 8
metastasis (8) 8
receptor protein-tyrosine kinases - genetics (8) 8
santé publique et épidémiologie (8) 8
tyrosine kinase inhibitors (8) 8
young adult (8) 8
[sdv.can]life sciences [q-bio]/cancer (7) 7
adenocarcinoma of lung (7) 7
alk (7) 7
antineoplastic combined chemotherapy protocols - adverse effects (7) 7
bevacizumab (7) 7
cancer therapies (7) 7
carcinoma, non-small-cell lung - secondary (7) 7
deoxycytidine - analogs & derivatives (7) 7
diagnosis (7) 7
disease progression (7) 7
dna methylation (7) 7
erlotinib (7) 7
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Lancet, The, ISSN 0140-6736, 2017, Volume 389, Issue 10072, pp. 917 - 929
Journal Article
Lancet, The, ISSN 0140-6736, 2016, Volume 387, Issue 10026, pp. 1405 - 1414
Journal Article
Lancet, The, ISSN 0140-6736, 2011, Volume 378, Issue 9796, pp. 1079 - 1088
Summary Background Platinum-based doublet chemotherapy is recommended to treat advanced non-small-cell lung cancer (NSCLC) in fit, non-elderly adults, but... 
Internal Medicine | SURVIVAL | MEDICINE, GENERAL & INTERNAL | MANAGEMENT | INTERNATIONAL-SOCIETY | GERIATRIC ASSESSMENT | UNDERREPRESENTATION | OLDER | OUTCOMES | COMBINATION | AGE | COMORBIDITY | Lung Neoplasms - drug therapy | Lung Neoplasms - mortality | Humans | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Male | Antineoplastic Agents - therapeutic use | Vinblastine - administration & dosage | Carboplatin - adverse effects | Carcinoma, Squamous Cell - mortality | Vinblastine - analogs & derivatives | Antineoplastic Agents - adverse effects | Aged, 80 and over | Female | Paclitaxel - administration & dosage | Drug Administration Schedule | Deoxycytidine - administration & dosage | Carboplatin - administration & dosage | Paclitaxel - adverse effects | Survival Rate | Adenocarcinoma - drug therapy | Carcinoma, Non-Small-Cell Lung - mortality | Carcinoma, Squamous Cell - drug therapy | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Aged | Carcinoma, Non-Small-Cell Lung - drug therapy | Deoxycytidine - analogs & derivatives | Adenocarcinoma - mortality | Clinical trials | Chemotherapy | Radiation therapy | Cancer therapies | Adenocarcinoma | Vinblastine | Carcinoma, Non-Small-Cell Lung | Antineoplastic Agents | Antineoplastic Combined Chemotherapy Protocols | Lung Neoplasms | Carcinoma, Squamous Cell | Life Sciences | Deoxycytidine | Paclitaxel | Carboplatin | Cancer
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 06/2018, Volume 378, Issue 24, pp. 2288 - 2301
The addition of atezolizumab (anti–PD-L1 antibody) to a platinum-based chemotherapy regimen improved progression-free survival among patients who had not... 
PHASE-III TRIAL | CELLS | MEDICINE, GENERAL & INTERNAL | MULTICENTER | THERAPY | BEVACIZUMAB | ANTIBODY | OPEN-LABEL | CANCER | DOCETAXEL | CHEMOTHERAPY | Lung Neoplasms - drug therapy | Lung Neoplasms - mortality | Humans | Middle Aged | Antibodies, Monoclonal - adverse effects | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Lung Neoplasms - pathology | Male | Vascular Endothelial Growth Factor A - antagonists & inhibitors | Carcinoma, Non-Small-Cell Lung - secondary | Anaplastic Lymphoma Kinase | Neoplasm Metastasis - drug therapy | Immunotherapy | Female | Paclitaxel - administration & dosage | Bevacizumab - administration & dosage | Carcinoma, Non-Small-Cell Lung - genetics | Carboplatin - administration & dosage | Carcinoma, Non-Small-Cell Lung - mortality | Genes, erbB-1 | B7-H1 Antigen - antagonists & inhibitors | Receptor Protein-Tyrosine Kinases - genetics | Antibodies, Monoclonal - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Survival Analysis | Aged | Carcinoma, Non-Small-Cell Lung - drug therapy | Mutation | Lung cancer, Non-small cell | Drug therapy | Research | Epidermal growth factor receptors | Liver | Non-small cell lung carcinoma | Oncology | Lymphocytes T | Metastasis | Cancer therapies | Patients | Bevacizumab | Metastases | Immunosuppression | Chemotherapy | Motivation | Medical prognosis | PD-L1 protein | Paclitaxel | Carboplatin | Population | Death | Vascular endothelial growth factor | Genotypes | Apoptosis | Tumors
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 06/2013, Volume 368, Issue 25, pp. 2385 - 2394
In a prospective, randomized, phase 3 trial of crizotinib as second-line therapy in patients who had disease progression while receiving a platinum-based... 
REARRANGEMENT | MEDICINE, GENERAL & INTERNAL | GEFITINIB | ONCOLOGY | EML4-ALK FUSION GENE | CLINICAL-TRIALS | PHASE-III | LYMPHOMA | OPEN-LABEL | DOCETAXEL | EGFR | Glutamates - therapeutic use | Lung Neoplasms - drug therapy | Pyrazoles - therapeutic use | Glutamates - adverse effects | Guanine - analogs & derivatives | Lung Neoplasms - mortality | Humans | Middle Aged | Male | Antineoplastic Agents - therapeutic use | Protein Kinase Inhibitors - adverse effects | Young Adult | Taxoids - therapeutic use | Pyridines - adverse effects | Antineoplastic Agents - adverse effects | Aged, 80 and over | Adult | Female | Guanine - adverse effects | Guanine - therapeutic use | Taxoids - adverse effects | Pyrazoles - adverse effects | Pyridines - therapeutic use | Kaplan-Meier Estimate | Carcinoma, Non-Small-Cell Lung - mortality | Pemetrexed | Disease-Free Survival | Protein Kinase Inhibitors - therapeutic use | Quality of Life | Aged | Carcinoma, Non-Small-Cell Lung - drug therapy | Tyrosine | Intravenous administration | Biomedical research | Lung cancer | Liver | Fatigue | Chromosome rearrangements | Cancer therapies | Patients | Lymphoma | Metastases | Ovarian cancer | Quality of life | Confidence intervals | Chemotherapy | Dyspnea | Alopecia | Platinum | Lymphomas | Respiration | Pharmaceutical industry | Protein-tyrosine kinase
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 06/2013, Volume 31, Issue 16, pp. 1997 - 2003
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 01/2002, Volume 20, Issue 1, pp. 247 - 253
Journal Article
Revue des Maladies Respiratoires Actualites, ISSN 1877-1203, 09/2016, Volume 8, Issue 5, p. 307
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 03/2016, Volume 34, Issue 7, pp. 661 - 668
Journal Article
JOURNAL OF THORACIC ONCOLOGY, ISSN 1556-0864, 05/2019, Volume 14, Issue 5, pp. 903 - 913
Introduction: This randomized phase II trial aimed at evaluating the engineered programmed cell death ligand 1 (PD-L1) antibody atezolizumab in SCLC... 
SCLC | Chemotherapy | MULTICENTER | ONCOLOGY | RESPIRATORY SYSTEM | Programmed cell death ligand 1 | OPEN-LABEL | BLOCKADE | Atezolizumab
Journal Article